Last reviewed · How we verify
Dibunafon (dibunate)
Dibunafon (generic name: dibunate) is a dibunate drug. It is currently in unknown development.
Dibunafon works by inhibiting the activity of certain enzymes in the body.
Dibunafon, also known as Dibunate Sodium, is a small molecule cough suppressant. It has been marketed under various names, including Becantyl, Becantex, and Linctussal, typically in dosages of 20 to 30 mg as a syrup or tablet.
At a glance
| Generic name | dibunate |
|---|---|
| Drug class | dibunate |
| Therapeutic area | Metabolic |
| Phase | unknown |
Mechanism of action
Imagine your body's cells have a factory inside them that produces chemicals. Dibunafon is like a brake pedal that slows down this factory, reducing the amount of chemicals produced. This can help treat certain conditions, but more research is needed to understand how it works and its potential effects on the body.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dibunafon CI brief — competitive landscape report
- Dibunafon updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Dibunafon
What is Dibunafon?
How does Dibunafon work?
What is the generic name of Dibunafon?
What drug class is Dibunafon in?
What development phase is Dibunafon in?
Related
- Drug class: All dibunate drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing